Compare NVST & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | ADMA |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | 12000 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 2019 | 2012 |
| Metric | NVST | ADMA |
|---|---|---|
| Price | $26.28 | $11.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $25.33 | ★ $32.00 |
| AVG Volume (30 Days) | 2.1M | ★ 3.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.31 | N/A |
| EPS | 0.28 | ★ 0.60 |
| Revenue | ★ $2,566,500,000.00 | $42,219,783.00 |
| Revenue This Year | $6.67 | $27.46 |
| Revenue Next Year | $3.55 | $22.11 |
| P/E Ratio | $88.86 | ★ $24.02 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $14.22 | $13.76 |
| 52 Week High | $30.42 | $25.67 |
| Indicator | NVST | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 23.94 |
| Support Level | $19.29 | N/A |
| Resistance Level | $30.18 | $16.44 |
| Average True Range (ATR) | 0.95 | 0.85 |
| MACD | -0.18 | -0.31 |
| Stochastic Oscillator | 44.78 | 0.18 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.